中概股收盘跌幅居前的个股为：天睿祥跌91.06%，Masonglory跌60.98%，苏轩堂跌27.54%，开心汽车跌 26.06%，朴荷生物科技跌23.6%。(格隆汇) | 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | TIRX | 天睿祥 | 0.118 | -91.06% | -1.202 | 1454.5万 | | MSGY | Masonglory | 0.800 | -60.98% | -1.250 | 555.96万 | | SXTC | 苏轩堂 | 0.0500 | -27.54% | -0.0190 | 216.08万 | | KXIN | 开心汽车 | 10.130 | -26.06% | -3.570 | 1.5亿 | | BYAH | 朴荷生物科技 | 0.0955 | -23.60% | -0.0295 | 68.43万 | ...

| 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | MSGY | Masonglory | 2.050 | -67.25% | -4.210 | 1715.17万 | | SXTC | 苏轩堂 | 0.0690 | -32.29% | -0.0329 | 382.74万 | | TDIC | Dreamland | 0.1876 | -18.68% | -0.0431 | 136.4万 | | DOGZ | 多尼斯 | 1.320 | -18.52% | -0.300 | 377.56万 | | TNMG | TNL Mediagene | 3.680 | -15.98% | -0.700 | 48.72万 | 中概股收盘跌幅居前的个股为：Masonglory跌67.25%，苏轩堂跌32.29%，Dreamland跌19.68%，多尼斯 跌18.528%，TNL Mediagene跌15.98%。(格隆汇) ...

TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced as part of its Artificial Intelligence (AI) Insight Initiative ...

Group 1: Company Performance - Gelteq Ltd (NASDAQ:GELS) shares rose sharply by 50.1% to $1.25 in pre-market trading after reporting positive preclinical results for its cannabinoid oral gel delivery platform [1][2] - The proprietary oral gel platform achieved a greater than 22% increase in the bioavailability of cannabidiol compared to an existing FDA-approved oil-based product [1] Group 2: Other Notable Stock Movements - Inspire Veterinary Partners Inc (NASDAQ:IVP) gained 141.3% to $0.056 after filing a Certificate of Amendment to increase its authorized Class A common stock from 100 million to 700 million shares [5] - Oriental Culture Holding Ltd (NASDAQ:OCG) rose 40.8% to $0.016 following the board's approval of a special cash dividend of 5 cents per share [5] - XCF Global Inc (NASDAQ:SAFX) gained 30.2% to $0.22 after announcing expansion financing plans [5] - AiRWA Inc (NASDAQ:YYAI) rose 15.8% to $1.46 after a director purchased 1.109 million shares at an average price of $1.35 per share [5] - Autolus Therapeutics PLC (NASDAQ:AUTL) gained 7.3% to $1.47 after announcing preliminary fourth-quarter and FY25 revenue results [5] Group 3: Declining Stocks - Briacell Therapeutics Corp (NASDAQ:BCTX) fell 53.1% to $5.12 after announcing the pricing of a $30 million public offering [5] - Moolec Science SA (NASDAQ:MLEC) fell 19.8% to $3.94 after a previous jump of 19% [5] - Hub Cyber Security Ltd (NASDAQ:HUBC) fell 19.1% to $0.43 after gaining 56% on the previous day [5] - Trip.com Group Ltd (NASDAQ:TCOM) dipped 9.3% to $68.55 amid an investigation by China's SAMR for potential anti-monopoly violations [5]

Corporate Updates - China SXT Pharmaceuticals, Inc. (SXTC) surged 17.40% to $0.12 after announcing a registered direct offering valued at about $10 million, selling 66,666,666 Class A ordinary shares at $0.15 per share, strengthening its balance sheet and fueling investor optimism [2] - Rapid Micro Biosystems, Inc. (RPID) advanced 8.55% to $3.30 following the release of preliminary unaudited fourth-quarter and full-year 2025 revenue results, sparking a positive reaction in extended trading [3] - TG Therapeutics, Inc. (TGTX) gained 6.99% to $29.82 after announcing preliminary U.S. net product revenue for its multiple sclerosis therapy BRIUMVI for the fourth quarter and full year 2025, along with 2026 financial guidance and development milestones [4] - argenx SE (ARGX) rose 2.00% to $826.72 after the FDA accepted for priority review a supplemental Biologics License Application for VYVGART, with a PDUFA target action date of May 10, 2026, indicating potential for expanded indications [5] - Clene Inc. (CLNN) edged higher by 0.98% to $5.15 after announcing an in-person Type C Meeting with the FDA, representing an important step in advancing its pipeline [6] Market Reactions - Cosmos Health Inc. (COSM) climbed 6.09% to $0.4961 despite no company-specific news, highlighting speculative interest and momentum trading in the micro-cap healthcare space [3] - Entera Bio Ltd. (ENTX) gained 4.11% to $1.52 in after-hours trading, reflecting investor activity around small-cap biotech names despite no new corporate updates [7]

New York, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $10 million for its client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (the “Company” or “China SXT”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Tr ...

Core Viewpoint - Bark Inc's shares experienced a significant increase of 19.9% to $0.74 in pre-market trading following a non-binding acquisition proposal from Great Dane, as disclosed in a 13D filing [1] Gainers - Signing Day Sports Inc saw a substantial gain of 43.7% to $0.71 in pre-market trading [4] - Ping An Biomedical Co Ltd rose by 34.3% to $0.27 after a previous decline of 68% on Friday [4] - Abivax SA increased by 23.6% to $141.35, with Morgan Stanley analyst Judah Frommer maintaining an Overweight rating and raising the price target from $101 to $145 [4] - Cellectar Biosciences Inc gained 18.4% to $3.65 after a 7% drop on Friday [4] - China SXT Pharmaceuticals Inc surged 17.5% to $0.18 following an 88% decline on Friday, announcing a $10 million registered direct offering [4] - Kingsoft Cloud Holdings Ltd increased by 13.8% to $12.55 [4] - Critical Metals Corp rose 12.3% to $16.82 after an 11% increase on Friday [4] - Rich Sparkle Holdings Ltd gained 11.7% to $97.00, following a 259% jump on Friday after announcing a $39 million offering of 3 million shares at $13 per share [4] - 3 E Network Technology Group Ltd rose 10.3% to $0.41 after announcing the closing of a $2 million convertible promissory note offering [4] Losers - Lexaria Bioscience Corp fell 12.9% to $0.65 after a 7% gain on Friday [4] - Plus Therapeutics Inc declined 11.8% to $0.49, announcing an offering of 22,321,429 pre-funded units at $0.56 per unit [4] - RenovoRx Inc fell 11.3% to $0.99 after a 3% decline on Friday [4] - Synchrony Financial dipped 9.5% to $78.61 [4] - Eastern International Ltd shares decreased by 9.1% to $1.41 after a 30% increase on Friday [4] - Stoke Therapeutics Inc declined 8.7% to $30.00, announcing updates to timelines for the completion of enrollment and Phase 3 data readout from the EMPEROR study [4] - Capital One Financial Corp fell 8.4% to $228.35 [4] - Bread Financial Holdings Inc tumbled 8.3% to $73.72 [4] - OSR Holdings Inc decreased by 8% to $0.61 after a 6% gain on Friday [4] - Himalaya Shipping Ltd dipped 5.7% to $8.72 [4]

Group 1: Market Activity - Several biotech and healthcare companies experienced notable gains in after-hours trading, indicating renewed investor interest in drug development and healthcare services [1] - Zentalis Pharmaceuticals, Inc. (ZNTL) surged 17.65% to close at $4.40, attributed to a recent corporate update that boosted investor confidence in its azenosertib development program [2] - LifeMD, Inc. (LFMD) climbed 12.18% to $4.33 following the announcement of a new senior secured revolving credit facility with Citizens Bank, providing up to $50 million in total availability [3] Group 2: Company-Specific Developments - NanoViricides, Inc. (NNVC) advanced 11.11% to $1.24, driven by speculative interest despite no recent news [4] - Intelligent Bio Solutions Inc. (INBS) posted a 9.10% increase, closing at $19.55, continuing to gain momentum from overall investor enthusiasm in the biotech sector [4] - IO Biotech, Inc. (IOBT) rose 6.49% to $0.60, suggesting bargain-hunting activity at lower price levels [5] Group 3: Financing and Agreements - China SXT Pharmaceuticals, Inc. (SXTC) advanced 2.06% to $18.29 after disclosing a definitive agreement for the purchase of 66,666,666 Class A ordinary shares at $0.15 per share, highlighting efforts to strengthen its capital position [6]

TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to t ...

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading, driven by corporate updates, clinical milestones, and acquisition speculation [1] Company Updates - China SXT Pharmaceuticals, Inc. (SXTC) saw a 13.6% increase to $1.42, following the announcement of its Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into product planning and market intelligence [2] - Revolution Medicines, Inc. (RVMD) surged 15.1% to $123.65 after reports of Merck's acquisition talks and the FDA granting Breakthrough Therapy Designation to its drug zoldonrasib for treating specific lung cancer patients [3] - KalVista Pharmaceuticals, Inc. (KALV) advanced 14.0% to $18.04 after reporting preliminary unaudited global net product revenue results for Q4 and the full year ended December 31, 2025, along with other operational indicators [4] - Zentalis Pharmaceuticals, Inc. (ZNTL) rose 8.1% to $3.07, likely due to investor reactions to a previous corporate update outlining key milestones for its drug azenosertib [5] - BriaCell Therapeutics Corp. (BCTX) gained 7.3% to $7.81 without new announcements, indicating momentum-driven trading [6] - Sagimet Biosciences Inc. (SGMT) increased 7.7% to $6.00 after announcing plans to present clinical trial results at an upcoming conference, highlighting anti-fibrotic effects observed in patients [7]